Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic

NicVAX(®), a nicotine vaccine (3’AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administration are associated with increased antibody response. This randomized, double-blinded...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatsukami, Dorothy K., Jorenby, Douglas E., Gonzales, David, Rigotti, Nancy A., Glover, Elbert D., Oncken, Cheryl A., Tashkin, Donald P., Reus, Victor I., Akhavain, Roxanne C., Fahim, Raafat E.F., Kessler, Paul D., Niknian, Minoo, Kalnik, Matthew W., Rennard, Stephen I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106715/
https://www.ncbi.nlm.nih.gov/pubmed/21270788
http://dx.doi.org/10.1038/clpt.2010.317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106715/
https://www.ncbi.nlm.nih.gov/pubmed/21270788
http://dx.doi.org/10.1038/clpt.2010.317

Ejemplares similares